Aβ43 in human Alzheimer’s disease: effects of active Aβ42 immunization

Table 1 Characteristics of the groups

	AD	iAD	p
N	21	16
Sex (% male)	48	56	0.60^a
Duration Dementia (years, mean ± sd)	8.5 ± 3.3	11.9 ± 4.5	0.02^b
Duration Dementia (years, mean ± sd)	n/a: n = 4
APOE genotype	2,2 or 2,3: 15%	2,2 or 2,3: 0%	0.45^a
	3,3: 15%	3,3: 25%
	3,4: 55%	3,4: 50%
	4,4: 15%	4,4: 25%
	n/a: n = 1	n/a: n = 4
Age at death (years, mean ± sd)	78.0 ± 7.5	79.2 ± 8.4	0.64^b
Survival time after immunization (months, mean ± sd)	N.A.	91.9 ± 57.7

Abbreviations: AD Alzheimer’s disease patients, iAD immunized Alzheimer’s disease patients, Aβ amyloid-β, N.A not applicable. n/a: not available.
Analysed by ^aPearsons’ chi-square and ^bt-test.

ISSN: 2051-5960